Purpose: To demonstrate whether inhibition of intestinal microbial beta (b)-glucuronidase (BGUS) abrogates tumor formation in a MMTV-PyMT mouse breast cancer model. Methods: Female MMTV-PyMT heterozygote mice (4 weeks old) were randomized to oral gavage with vehicle or UNC10201652 (20 µg/day), a microbial BGUS inhibitor, for 9 weeks. The entire animal carcass was assessed for tumor deposits by histology and immunohistochemical staining for tumor (Ki67, PCNA) and breast specific (ER, PR, Cyclin D1, aSMA, Integrin b1) markers. Results: The MMTV-PyMT breast pathology in our study simulates prior published reports of tumor incidence and aggressiveness. There was no significant difference in the tumor histology, number of tumors (lesions), and patterns of spread of tumors in the UNC10201652 versus the vehicle treated mice. Similarly, there were no significant differences in the semi-quantitative scores for expression of ER, PR, Ki67, PCNA, or Integrin b1. There were also no major differences seen in qualitative screening of Cyclin D1 and aSMA. Conclusions:
Introduction
Breast cancer afflicts one in eight women and is second to lung cancer in women with respect to cancer deaths [1] .
Hormone receptor-positive breast cancer constitutes the vast majority of cases of breast cancer world-wide [2, 3] .
Recently, it has been proposed that the human intestinal tract houses bacteria that may intrinsically convert metabolized estrogen (in the form of estrogen glucuronide) to the parent hormone, estrogen, via actions of microbial specific enzymes, beta (b)-glucuronidase (BGUS) [4, 5] . This axis of re-purposing parent estrogen in normal physiology, termed the "estrabolome", is a likely mechanism to keep estrogen levels fine-tuned in our bodies [4, 6] .
The evidence supporting this concept is demonstrated by human studies whereby the intestinal microbiome composition affects the levels of systemic estrogen [7] [8] [9] [10] . Fecal BGUS activity in women correlate with reduced levels of plasma concentration of estrogen [11] . In a recent paper, using conjugated estrogens and bazedoxifene, manipulation of fecal BGUS activity was achieved to lower systemic estrogen levels in mice to levels commensurate with what might be alleviate menopause-associated symptoms in women [10] . In addition, nipple aspirate microbial BGUS activity (as well as associated microbial species) were significantly elevated in breast cancer cases versus healthy controls [12] . Studies of chemically-induced mammary carcinogenesis in mice suggest that diets that lower microbial BGUS activity in cecal contents are associated with lower incidence of mammary tumor, albeit with no change in circulating estrogen levels [13] . Indeed, microbial BGUS enzymes have been implicated in carcinogen metabolism, which could confound interpretation of these models in terms of BGUS activity and protection against breast carcinogenesis [14, 15] . Overall, there is compelling human data suggesting a link between microbial BGUS activity either in feces and/or nipple aspirates with systemic estrogen availability and cancer association. This link has not been investigated systematically in non-chemically induced (i.e. genetic) models simulating human breast carcinogenesis. Specifically, no genetic models of breast cancer in rodents have been analyzed with intestinal BGUS modulating compounds. In this regard, a well-studied mouse model of breast tumor progression, the MMTV-PyMT 634 mice, is endowed with the development of early lesions (hyperplasia/adenoma) that are strongly estrogenreceptor positive, and this was a key driver of our present study [16, 17] . This mouse model has been extensively and reproducibly characterized with respect to dietary interventions and tumor progression stages and hormonereceptor status and other biomarkers [16, [18] [19] [20] [21] [22] [23] [24] [25] . With respect to our hypothesis, if the intestinal "estrabolome" had significant estrogen metabolic effects, it might be conceivable that the development of early lesions (e.g., hyperplasia/adenoma) might drive lesions forward towards a frank carcinoma due to the availability of recirculating estrogen. However, specific strategies would then be needed to ablate intestinal BGUS in order to demonstrate a cause-and-effect of the "estrabolome" hypothesis.
In contrast with clinical and rodent "association" studies that have been published to-date, it has not been feasible to prove "causation" of effect when microbial-specific BGUS is ablated in vivo. In this regard, until recently, there were no specific inhibitors or strategies available to reduce microbial BGUS in any organ and thus show its direct effect on reducing breast carcinogenesis. Recently, though, BGUS inhibitors have been developed that are potent, selective toward microbial GUS enzymes, and non-lethal to microbial cells [26] . These inhibitors were initially employed to block the reactivation of the active metabolite of the solid tumor chemotherapeutic irinotecan in the intestinal lumen, and were shown to significantly reduce gut damage and resultant diarrhea in mice [27, 28] . The active metabolite of irinotecan, SN-38, is glucuronidated to inactive SN-38-G in the liver and other protective tissues by Phase II drug metabolizing UGT enzymes [29] . SN-38-G is sent to the gut for excretion, where it is subject to reactivation by microbial BGUS, leading to sufficient SN-38 in the GI tract to cause intestinal damage and the dose-limiting side effect of irinotecan, delayed diarrhea. The initial compound characterized, Inhibitor 1, was shown to have no effect on circulating plasma levels of irinotecan or its key metabolites [30] . Inhibitor 1 was also shown to block small intestinal ulcers caused by the non-steroidal anti-inflammatory drugs diclofenac, indomethacin and ketoprofen, which are all glucuronidated and subject to reactivation by microbial BGUS [31] [32] [33] [34] . Inhibitor 1 was found to have no effect on plasma levels of diclofenac in mice [31] . Finally, in 2018, it was shown that Inhibitor 1 blocks anastomotic leakage after intestinal resection in rats given diclofenac [35] . Thus, a potent and specific BGUS inhibitor that does not kill microbial cells has been shown to be effective in blocking several negative outcomes with drugs or surgical
interventions.
An improved BGUS inhibitor, UNC10201652, was recently described that highjacks the catalytic cycle of the BGUS active site, utilizing a piperizine warhead to form a long-lived covalent inhibitor-glucuronide bound to the active site of the enzyme [36] . As such, this compound is more potent than Inhibitor 1, as demonstrated recently in detailed analyses of several human gut microbial BGUS enzyme orthologs, their processing of drug and non-drug substrates, and the inhibition of these reactions [37, 38] . Thus, we chose to examine the effects that UNC10201652 has on the development of breast tumors in the PyMT mouse model of hormone receptor positive tumorigenesis.
Methods

Mice
MMTV-PyMT 634 heterozygote male mice were a generous gift from Jeffrey Pollard PhD (Albert Einstein College of Medicine, Bronx, NY) [17] and bred (crossed to female FVB, code 27, Charles River) in our vivarium.
At each successive breeding generation, all pups (male and female) were genotyped and separated in cages (after weaning) based on gender. Female (4 weeks old) mice generated from each breeding pair were randomly allocated to one of two treatment groups (n = 15/treatment group; total n = 30 female mice generated over a 24 month period) using a coin-toss approach as previously utilized [39] . Cage allocation was also determined by coin toss and to maintain homogeneity in the microbiome exposure, within each treatment group, mice were randomly shuffled between their respective treatment group cages prior to treatment group assignment (e.g., mouse 1 on day 1 was in cage 1, then on day 2 allocated to cage 3 within its respective treatment group etc.). Mice were treated in metabolic cages to limit communal coprophagy. The control group consisted of oral gavage with vehicle (0.67 % DMSO/0.9% saline; 100 µl) and the treatment group, UNC10201652 (Inh9, 20 µg/day) gavaged (in 0.67 %DMSO/0.9% saline; 100 µl), each starting day 1 week 3 after weaning (4 week old mice) and consecutively dosed daily for 9 weeks. Dosing was omitted over weekends (2 days) but resumed each starting weekday (Monday).
Gavage was necessary as prior studies in our laboratory showed that mice are averse to consuming UNC10201652in water due to poor taste. UNC10201652 is also poorly soluble in water. Mice under 4 weeks of age cannot tolerate gavage with UNC10201652.
Mice were fed standard laboratory chow (Lab Diet, #5058) and animal facility water as provided for all barrier facility mice. They followed a standard 12h sleep-wake cycle and all cages were housed in the same room and in the same rack. Fecal pellets were collected from each mouse at baseline and at necropsy. Euthanasia and distress relief intervention was conducted strictly according to the approved Institute for Animal & Use Care 
Genotyping
Mice were genotyped exactly as previously described and published and using primer sets as described in above [40] . The representative PCR gel for mouse genotyping and classification is shown in Supplementary Figure   1 . The genotyping primer sets for PCR:
The expected band size is 556 bp ( Supplementary Figure 1 ).
Histopathology
For each mouse, all mammary glands were collected. Two of the mammary glands, as well as all lung lobes, were assigned for histopathologic examination by a board-certified veterinary pathologist (APB). Tissues for histopathology were fixed for 48 hours in 10% neutral buffered formalin and then routinely processed for paraffin embedding, sectioning, and staining by the Albert Einstein Cancer Center Histology and Comparative Pathology Facility. Each sample was sectioned at three levels (separated by 100 µm) in duplicate (i.e. each level had 2 slides) for assessment of lesion morphology. The lesions determined included hyperplasia, adenoma, early carcinoma and late carcinoma. Histopathological examination of the mammary tumors of each mouse was conducted and when present, lesions were categorized as hyperplasia, adenoma/mammary intraepithelial neoplasia (MIN), early carcinoma and late carcinoma as per previous work with PyMT mice [17] .
Slides were H&E stained using a standard protocol and imaged with a Zeiss AxioImager A.2 microscope and Zeiss Axiocam 305 color using ZEN software. The histologic lesions satisfying the definitions of hyperplasia, adenoma, early and late carcinoma were then individually ascertained across an entire slide and their areas (defined by a percentage of the grids covered) were expressed as an approximate percentage (%) of the total area of the mammary gland on that slide.
Immunohistochemistry
Immunohistochemical staining was performed using the following antibodies: estrogen receptor alpha [41] , which suggest the assessment of at least three randomly selected high-power fields (HPF), providing that staining is homogenous across the section. The percentage of positively stained neoplastic cells for PCNA was also assessed across three randomly selected HPF (400x).
Statistical Analysis
The published literature of chemoprevention studies using the MMTV-PyMT mouse model [19, 22, 42] suggests that potential drugs that could have chemoprevention properties have a standardized effect size (SES) that range between 20-80% (0.2 to 0.5). The assumption of our analysis is based on the fact that ~90-100% of the MMTV-PyMT mice at 12-14 weeks develop tumors covering the entire spectrum of histology evaluated [17] . If we assume that over a 24-month period, we can efficiently generate and study 30 mice (~ based on breeding we estimate obtaining 1-2 females per month and conducting the experiment in a staggered manner), to show an SES of > 55% assuming a common standard deviation (30%) we would require 24 mice totally (distributed in a 1:1 treatment allocation manner). This assumes a two-tailed analysis of outcome with 95% power and a = 0.05 (https://www.stat.ubc.ca/~rollin/stats/ssize/n2.html). The experiment inflation factor (loss of mice prior to start of randomization like premature demise) is <20% (0.2), then the total sample size required would be 30 mice [43] . An intent-to-treat analysis was conducted on all mice and outcomes.
One-way analysis of variance (1-Way ANOVA) as well as Two-way analysis of variance (2-Way ANOVA),
with Sidak's test for multiple comparisons conducted in swapped fashion, as well as diagnostics for residuals using Spearman's rank correlation test for heteroscedasticity and for gaussian distribution of residuals, were calculated using GraphPad Prism version 8.2.0 (272) for macOS (GraphPad Software, La Jolla, California, USA).
Results
The Morphology of MMTV-PyMT mouse tumors. All mice examined (in both control and treatment groups) exhibited similar histologic findings. Mammary tissue contained a range of abundant proliferative lesions, from hyperplasia to adenoma/MIN to carcinoma. Hyperplastic foci consisted of ducts lined by one to several layers of jumbled epithelial cells that were polygonal, with indistinct cell borders, a small amount of pale amphophilic cytoplasm and round vesicular nuclei with variably prominent nucleoli. Anisocytosis and anisokaryosis (pleomorphism) were minimal and mitoses were rare. The hyperplastic ducts were surrounded by a distinct and intact basement membrane. Foci of adenoma/MIN were characterized by a more florid epithelial proliferation than hyperplasia, but still confined by an intact basement membrane (no invasion). The acini and ducts were filled and expanded by epithelial cells with similar characteristics as in the hyperplastic foci, though the cells in adenoma /MIN exhibited slightly more anisocytosis, anisokaryosis and mitoses (up to 3/400x field). There were frequent coalescing foci of carcinoma, in which epithelial cells showed features as described above in adenoma/MIN but with increased pleomorphism and mitoses (6-10/400x field). Importantly, there was also a lack of distinct/intact basement membrane with invasion of the neoplastic cells into adjacent stroma/fibroadipose tissue. Multifocally, there was frequent and abundant central necrosis within the carcinomas. There were also foci that exhibited features of late stage carcinoma, with solid sheets of epithelial cells with no remaining acinar structures visible. The lung metastases were evaluated both grossly and by microscopy. They were qualitatively similar in the number of lesions, the area of lung involvement and size in both the vehicle and UNC10201652 treated groups (Figure 1 A-E) .
UNC10201652 does not alter the tumor incidence in MMTV-PyMT mice. The entire mouse carcass was dissected and all mammary glands removed. The assigned veterinary pathologist (APB) randomly picked two mammary glands and lungs for histologic reading at three levels cut into the prepared tissue block. The levels were numbered serially (1, 2 and 3) and two percentage counts (2 slides evaluated at each level) for each tumor histology (hyperplasia, adenoma, early carcinoma and late carcinoma) was generated. The minimum % area of hyperplasia, adenoma, early carcinoma and late carcinoma, were not significantly different between the control and UNC10201652 treated group, respectively (Figure 2A-C) . Similarly, the maximum % area of hyperplasia, adenoma, early carcinoma and late carcinoma, were also not significantly different between the control and UNC10201652 treated group, respectively ( Figure 2D-F) .
UNC10201652 does not alter the breast tumor marker distribution in MMTV-PyMT mice.
Estrogen Receptor (ERa). ER is expressed largely in hyperplastic and adenomatous lesions in MMTV-PyMT tumors [17] . The tumor and surrounding mammary tissues were assessed for ER expression in our mice. The semiquantitative scoring of positive staining was analyzed ( Figure 3A, upper panel) and represented numerically. The expression score is significantly lower in the carcinoma stage as compared with either hyperplasia or adenoma (p < 0.0001, Two-way ANOVA followed with Sidak's test). There is no significant difference within each lesion type between the two treatment groups for the extent of ER-positivity ( Figure 3A , lower panel).
Progesterone Receptor (PR). Similar to ER, PR is expressed largely in hyperplastic and adenomatous lesions in
MMTV-PyMT tumors [17] . Additional staining was conducted using antibodies targeting PR. The semi-quantitative scoring of positive staining was analyzed ( Figure 3B, upper panel) and represented numerically. The expression score is significantly lower in the carcinoma stage as compared with either hyperplasia or adenoma (p < 0.0001, Two-way ANOVA followed with Sidak's test). As with ER, there was no significant difference within each lesion type between the two treatment groups for the extent of PR-positivity ( Figure 3B , lower panel).
Her2/neu. Her2/neu is expressed is low abundance in hyperplasia and its score intensity rises with the progression of the lesion reaching highest levels in late carcinomas [17] . For Her2/neu, the semi-quantitative scoring of positive staining was analyzed ( Figure 3C , upper panel) and represented numerically. However, unlike prior published data [17] , we were unable to find significant differences in the semi-quantitative scoring between lesion types in our mice p = 0.647, Two-way ANOVA followed with Sidak's test). By visual inspection, there was a trend, however, for increased Her2/neu expression in the more advanced stages beyond adenomas within each treatment group. There was no significant difference within each lesion type between the two treatment groups for the extent of PRpositivity ( Figure 3C, lower panel) .
Ki67. Ki67 is a reliable marker for testing proliferation in early and late breast tumor lesions (~40-85% positive staining depending on the lesion type) in the MMTV-PyMT mouse (albeit C57BL/6J background) model [44] . In this analysis, we looked at all lesions in a given HPF in a slide and the semi-quantitative "average" scoring of positive staining (in 3 random HPF) was analyzed ( Figure 3D, upper panel) and represented numerically. Our staining percentages ~ 35-77% are similar in quality and percent of cells expressing Ki67-positivity to published data [44] . There was no significant difference within each lesion type between the two treatment groups for the extent of PR-positivity ( Figure 3D, lower panel) .
Proliferating Cell Nuclear Antigen (PCNA). Similar to Ki67, for PCNA staining a semi-quantitative "average" scoring of positive staining (in 3 random HPF) was analyzed ( Figure 3D, upper panel) and represented numerically.
There was no significant difference within each lesion type between the two treatment groups for the extent of PRpositivity ( Figure 3D, lower panel) .
Cyclin D1. Cyclin D1 is robustly elevated as lesions progress from hyperplasia to frank carcinoma and the distribution of the positive staining within the lesion varies [17] . At the hyperplasia and adenoma/MIN stage, cyclin D1 positively stained cells were mainly located at the outer margins of the proliferative lesions, while at both early and late carcinoma stages, there were increased numbers of cyclin D1-positive cells within the tumors, as well as distribution of the positive cells throughout the entire tumor ( Figure 3E ). α-SMA. Immunostaining for α-SMA was utilized to stain myoepithelial cells. In hyperplastic lesions, similar to normal/unaffected mammary duct, myoepithelial cells form a single complete layer upon which luminal epithelial cells sit. Adenoma/MIN lesions were surrounded by a single layer of myoepithelial cells, though there were multiple foci in which the layer appeared incomplete. In more advanced lesions (carcinomas), the myoepithelial cell layer was completely disrupted and lost. (Figure 3F ).
Integrin β1. For Integrin β1, which is only marginally expressed in MMTV-PyMT tumors and decreases as the lesion advances [17] , the semi-quantitative scoring of positive staining was analyzed ( Figure 3G, upper panel) and
represented numerically. The expression score is significantly lower in the carcinoma stage as compared with either hyperplasia or adenoma (p < 0.0001, Two-way ANOVA followed with Sidak's test). There was no significant difference within each lesion type between the two treatment groups for the extent of PR-positivity ( Figure 3G , lower panel).
Discussion
Our results show that when MMTV-PyMT mice are administered UNC10201652, a potent BGUS inhibitor, the incidence of breast tumor (and tumor initiating) lesions ranging from hyperplasia to frank carcinoma is not significantly changed. There is a trend, however small, that the incidence of hyperplastic and adenomas may be decreased in UNC10201652 treated mice; however, as we will discuss this would require a different experimental setup to clarify. To our knowledge this is the first report of use of any BGUS inhibitor in chemoprevention of breast tumors using a genetic model simulating human breast cancer.
There are no mouse transgenic breast cancer models that are truly representative of human ER+ tumors, especially luminal A tumors. The p53 +/model developed by Dan Medina at Baylor [45] does closely simulate ER+ breast cancers. Also, mice with mammary gland expression of constitutively active AKT (myrAKT) develop ER+ tumors upon DMBA treatment [46] . To our knowledge, this might be the closest model to human tumors (because PI3K activating mutations are reasonably common in human ER+ cancers, although activating mutations of AKT are less common), however it is quite time-consuming. These models require carcinogen promotion and for purposes of evaluating enzymes that might alter carcinogen metabolism (e.g., microbial BGUS) [47] , these models are not tractable for the study of tumor prevention. On the other hand, the MMTV-PyMT tumor model is tractable as it does not involve use of carcinogens to promote tumor formation; relies on a "natural" progression of discrete steps in mammary carcinogenesis; and could potentially be used for the study of male (unpublished observations, Mani Laboratory, Bronx, NY) and female breast cancer development [16] .
The results of our study have caveats that raise the need for further experimentation to definitely evaluate the effect of BGUS inhibition in breast tumorigenesis. First, several transgenic and knockout breast cancer models need to be evaluated and their results compared with our MMTV-PyMT mice [48] . It is conceivable that the effect we see if specific to this model. Second, an in-depth evaluation of the level of microbial BGUS inhibition (feces) by UNC10201652 needs to be performed in the MMTV-PyMT mice to determine the extent to which inhibition of all relevant BGUS enzymes occurs at the chosen dose (20 µM/day). It is important to note that this dose was chosen based on prior observations that BGUS inhibition at this dose are effective in vivo across several mouse models [27, 28, 31, 35] . In this context, evaluation of the intestinal and breast microbiota in terms of any major changes in species/class/phyla using 16S or other metagenomic sequencing needs to be carried out. The animal models also need to be evaluated in terms of their metabolomics -in particular, fecal, serum and breast concentration of estrogen and its major metabolites, glucuronides and sulfates. Third, use of systemically bioavailable BGUS inhibitors would be of great use in the study of whether breast nipple fluid BGUS inhibition (resident bacteria in the duct fluid also express BGUS enzymes; changing the nipple aspirate "estrabolome") also lowers re-absorbed estrogen in the glands and reduces tumor formation locally [5] .
Our study shows a minor but potentially interesting trend in the data. We find a trend favoring lower rates of hyperplastic and adenomatous lesions, as well as lower Ki67 and PCNA scores in MMTV-PyMT mice treated with UNC10201652. While this may be a spurious result, these observations may well be correct since our mouse model started chemoprevention at 4 weeks of age. In this model, at 4 weeks, most mice have already initiated tumor development [17] . Indeed, if we know that the highest expression of ER is in the early lesions (hyperplasia, adenoma), then it is likely that bioavailable estrogen could potently drive early lesion formation and/or development [17] . Thus, reducing overall estrogen exposure in breast tissue early at birth would be critical in addressing this problem. A re-design of our experiments would be necessary to address protection against the development of hyperplasia/adenoma and several approaches could be considered. One could be the treatment of the mother of the index MMTV-PyMT mouse with BGUS inhibitors that are excreted in mammary milk. The female pups would then be exposed to BGUS inhibitors at birth and through weaning. The other could be attempting to solubilize UNC10201652 in other media such as milk or create tasteless formulations for oral gavage. In this context, perhaps injectable (intravenous, subcutaneous) formulations may also be considered. Thus, overall, formulations for solubility and palatability coupled with early delivery via milk or water is indicated with a study limited to 2-4 weeks.
In the context of using BGUS inhibitors to target chemotherapy toxicity [27] , our study provides some valuable groundwork in terms of safety and effects on cancer progression, especially in advanced stages. Our data clearly shows that there is no biologically or statistically significant enhancement of tumor progression or late tumor incidence by UNC10201652. Thus, it is safe to use UNC10201652 in MMTV-PyMT mice in conjunction with other chemotherapeutics in attempts to enhance anti-tumor efficacy while potentially lowering GI toxicity. *There was no significant difference in any tumor type between treatment groups (Two-way ANOVA followed with Sidak's test, p > 0.1) at any level evaluated. ** There was no significant difference in any tumor type between treatment groups (One-way ANOVA followed with Sidak's test, p > 0.1) at any level evaluated. 
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